References
- Fotopoulou C, Hall M, Cruickshank D, et al. British Gynaecological Cancer Society(BGCS)epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. European Journal of Obstetrics and Gynaecology and Reproductive Biology. 2017;213:123–139. doi:https://doi.org/10.1016/j.ejogrb.2017.04.016.
- Griffiths CT, Parker LM, Fuller AF. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treatment Reports. 1979;63:235–240.
- Luyckx M, Leblanc E, Filleron T, Morice P. Maximal Cytoreduction in Patients with FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice. A retrospective French Multicentric Study. Int J Gynaecol Cancer. 2012;22:1337–1343. doi:https://doi.org/10.1097/IGC.0b013e31826a3559.
- Bacalbasa N, Balescu I, Dima S, Brasoveanu V, Popescu I. Hematogenous Splenic Metastases as an Independent Negative Prognosis Factor at the Moment of Primary Cytoreduction in Advanced Stage Epithelial Ovarian Cancer – A Single Center Experience. Anticancer Research. 2015;35(10):5649–5654.
- Rose PG, Piver MS, Tsukada Y, Lau TS. Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer. 1989;64(7):1508–1513. doi:https://doi.org/10.1002/1097-0142(19891001)64:7<1508::AID-CNCR2820640725>3.0.CO;2-V.
- Davies JM, Lewis M, Wimperis J, Rafi I, Ladhani S, Bolton-Maggs PHB. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: Prepared on behalf of the British Committee for Standards in Haematology by a Working Party of the Haemato‐Oncology Task Force. British Journal of Haematology. October 2011;155(3):308–317.
- Suidan RS, Leitao MM, Zivanovic O, et al. Predictive Value of the Age-Adjusted Charlson Comorbidity Index on Perioperative Complications and Survival in Patients Undergoing Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer. Gynaecology Oncology. 2015;138(2):246–251. doi:https://doi.org/10.1016/j.ygyno.2015.05.034.
- Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association. June 1958;53(282):457–481.
- Ziaoxin YI, Xiaofei W, Speicher PJ, et al. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. Journal of the National Cancer Institute. 2017;109(8)109–323. doi:https://doi.org/10.1093/jnci/djw323
- Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Statistics in Medicine. 2014;33:1252–1258. doi:https://doi.org/10.1002/sim.5984.
- Heinze G, Juni P. An overview of the objectives of and approaches to propensity score analyses. European Heart Journal. 2011;32:1704–1708. doi:https://doi.org/10.1093/eurheartj/ehr031.
- DiPrete T, Gangl M. Assessing Bias in the Estimation of Causal Effects: Rosenbaum Bounds on Matching Estimators and Instrumental Variables Estimation with Imperfect Instruments. Sociological Methodology. 2004;34:271–310. doi:https://doi.org/10.1111/j.0081-1750.2004.00154.x.
- R Foundation for Statistical Computing. R: A language and environment for Statistical Computing. 2018. Available at: https://www.R-project.org.
- Tiwana KK, Nibhoria S, Kaur M, Monga T, Gupta R. Postchemotherapy Histopathological Evaluation of Ovarian. Chemotherapy Research and Practice. January 2015;2015(3):298–302.
- Eisenkop SM, Spirtos NM, Wei-Chien ML. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynaecoloic Oncology. 2006;100:344–348. doi:https://doi.org/10.1016/j.ygyno.2005.08.036.
- Llueca JA, Herraiz LJ, Catala C, Serra A, Rivadulla I, Escrig J. Effectiveness and Safety of Cytoreduction Surgery in Advanced Ovarian Cancer: Initial Experience at a University General Hospital. Journal of Clinical Gynaecology & Obstetrics. 2015;4(3):251–257. doi:https://doi.org/10.14740/jcgo345w.
- Kuhn W, Florack G, Roder J. The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV. International Journal Gynaecological Cancer. 1998;8:56–63.
- Chi DS, Eisenhaur EL, Zivanovic O. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynaecologic Oncology. 2009;114:26–31. doi:https://doi.org/10.1016/j.ygyno.2009.03.018.
- Kommoss S, Rochon J, Harter P, Heitz F. Prognostic Impact of Attitional Extended Surgical Procedures in Advanced-Stage Primary Ovarian Cancer. Annals of Surgical Oncology. 2010;17:279–286. doi:https://doi.org/10.1245/s10434-009-0787-8.
- Vergote I, Trope C, Amant F. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV Ovarian Cancer. New England Journal Medicine. 2010;262:943–53. doi:https://doi.org/10.1056/NEJMoa0908806.
- Tanner EJ, Long KC, Feffer JB. Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer. Gynaecologic Oncology. 2013;128:28–33. doi:https://doi.org/10.1016/j.ygyno.2012.09.019.
- Fagotti A, Vizzielli G, Ferrandina G, Fanfani F, Gallotta V, Chiantera V. Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial). European Journal Of Cancer. 2016;48:22–33. doi:https://doi.org/10.1016/j.ejca.2016.01.017.
- Turnbull HL, Akrivos N, Wemyss-Holden S. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer. Arch Gynecol Obstet. 2017;295:681–687. doi:https://doi.org/10.1007/s00404-016-4265-9.
- Kalampokas E, Young H, Bednarek A, et al. Surgical Outcomes and Morbidity After Radical Surgery for Ovarian Cancer in Aberdeen Royal Infirmary, the Northeast of Scotland Gynaecologic Oncology Centre. Anticancer Research. 2018;38(2):923–928.
- Fotopoulo C, Jones B, Savvatis K, et al. Maximal Effort Cytoreductive Surgery for Disseminated Ovarian Cancer in a UK Setting: Challenges and Possibilities. Archives of gynaecology & obstetrics. 2016;294(3):607–614. doi:https://doi.org/10.1007/s00404-016-4080-3.
- Hall M, Savvatis K, Nixon K, et al. Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome. Annals of Surgical Oncology. 2019;26(9):2943–2951. doi:https://doi.org/10.1245/s10434-019-07516-3.
- Zapardiel I, Peiretti M, Zanagnolo V, et al. Splenectomy as Part of Primary Cytoreductive Surgery for Advanced Ovarian Cancer: A Retrospective Cohort Study. International Journal of Gynaecological Cancer. 2012;22:968–973. doi:https://doi.org/10.1097/IGC.0b013e3182571479.
- Acosta-Torres S, Fader AN. Laparoscopic splenectomy for secondary cytoreduction of ovarian cancer in a woman with localized splenic recurrence. Gynecologic Oncology. Mach 2020;156(3):744–745.
- McCann CK, Whitfield BG, Munro GE, Del Carmen MG. Prognostic Significance of Splenectomy as Part of Initial Cytoreductive Surgery in Ovarian Cancer. Annals of Surgical Oncology. 2011;18:2912–2918. doi:https://doi.org/10.1245/s10434-011-1661-z.
- Magtibay PM, Adams PB, Silverman MB, Cha SS, Podatz KC. Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynaecologic Oncology. 2006:369–374. doi:https://doi.org/10.1016/j.ygyno.2006.03.028.
- Phillips AJ, Sudha S, Singh K, et al. The NICE classification for “Ultra-radical (extensive) surgery for advanced ovarian cancer” guidance does not meaningfully predict post-operative complications: a cohort study. BJOG An International Journal of Obstetrics & Gynaecology. 2018;126:96–104. doi:https://doi.org/10.1111/1471-0528.15423.
- Prehn RT. The paradoxical effects of splenectomy on tumour growth. Theoritical Biology and Medical Modelling. 2006;3.
- Mellemkjøer L, Olsen JR, Linet MS, Gridley G, McLaughlin JK. Cancer risk after splenectomy. Cancer. 1995;75:577–583. doi:https://doi.org/10.1002/1097-0142(19950115)75:2<577::AID-CNCR2820750222>3.0.CO;2-K.
- Linet MS, Nyrien O, Gridley G, et al. Risk of cancer following splenectomy. International Journal of Cancer. 1996;66:611–616. doi:https://doi.org/10.1002/(SICI)1097-0215(19960529)66:5<611::AID-IJC5>3.0.CO;2-W.
- Erturk S, Ersan Y, Cicek Y. Effect of Simultaneous Splenectomy on the Survival of Patients Undergoing Curative Gastrectomy for Proximal Gastric Carcinoma. Surgery Today. 2003;33:254–258. doi:https://doi.org/10.1007/s005950300057.
- Phillips A, Pounds R, Balega J, Singh K. Histopathological correlation of splenic disease with radiological and surgical findings: Should we incorporate splenectomy into standard procedures for disseminated Müllerian adenocarcinoma? European journal of gynaecological oncology. 2016;37:678–684.
- Bilgin T, Ozerkan K, Ozan H. Splenectomy in cytoreductive surgery for advanced ovarian cancer. Archives of Gynaecology & Obstetrics. 2005;271:329–331. doi:https://doi.org/10.1007/s00404-004-0612-3.
- Manci N, Bellati F, Muzii L, et al. Splenectomy During Secondary Cytoreduction for Ovarian Cancer Disease Recurrence: Surgical and Survival Data. Annals of Surgical Oncology. 2006;12:1717–1723. doi:https://doi.org/10.1245/s10434-006-9048-2.
- AYHAN A, AL R, BAYKAL C, DEMIRTAS E. The influence of splenic metastases on survival in FIGO Stage IIIC epithelial ovarian cancer. International Journal Gynaecological Cancer. 2004;14:51–56. doi:https://doi.org/10.1136/ijgc-00009577-200401000-00006.
- Chen Lm, Leuchter RS, Lagasse LD, Karlan BY. Splenectomy & Surgical Cytoreduction for Ovarian Cancer. Gynecolgic Oncology. 2000;77:362–368. doi:https://doi.org/10.1006/gyno.2000.5800.
- Eisenhauer EL, Abu-Rustum NR, Sunoda Y. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patietns with stages IIIC-IV epithelial ovarian cancer. Gynaecologic Oncology. 2006;103:1083–1090. doi:https://doi.org/10.1016/j.ygyno.2006.06.028.
- Sehouli J, Senyuva F, Fotopoulou C, et al. Intra-Abdominal Tumer Dissemination Pattern and Surgical Outcome in 214 Patients with Primary Ovarian Cancer. Journal of Surgical Oncology. 2009;99:424–427. doi:https://doi.org/10.1002/jso.21288.
- Sun H, Bi Z, Yang J, Wu M, Pan L. Splenectomy During Cytoreductive Surgery in Epithelial Ovarian Cancer. Cancer Management & Research. 2018;10:3473–3482. doi:https://doi.org/10.2147/CMAR.S172687.
- Nicklin JL, Copeland LJ, O'Toole RV, Lewandowski GS, Vaccarello L, Havenar LP. Splenectomy as Part of Cytoreductive Surgery for Ovarian Carcinoma. Gynaecologic Oncology. 1995;58:244–247. doi:https://doi.org/10.1006/gyno.1995.1218.